| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Parishin C targets the central nervous system, with potential activity at GABAergic and dopaminergic pathways. It may modulate neurotransmitter systems involved in anxiety, insomnia, and cognitive function. Its exact molecular targets are not fully elucidated but are related to its neuroprotective effects.
|
|---|---|
| ln Vitro |
In vitro, parishin C has been shown to exhibit antioxidant activity, protecting neuronal cells from oxidative stress-induced damage. It may also inhibit the activity of monoamine oxidase (MAO) and acetylcholinesterase (AChE), enzymes involved in neurotransmitter metabolism.
|
| ln Vivo |
In vivo, parishin C has been studied in animal models of anxiety and insomnia. It has been shown to prolong sleep time and reduce locomotor activity in mice, suggesting sedative and hypnotic effects. It also improves cognitive function in models of memory impairment.
|
| Enzyme Assay |
In vitro enzyme assays are performed using purified MAO or AChE enzymes. Parishin C is incubated with the enzyme and a specific substrate, and enzyme activity is measured by spectrophotometric or fluorometric methods. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Neuronal cell lines (e.g., PC12 or SH-SY5Y cells) are cultured and treated with parishin C. Cell viability is assessed under oxidative stress conditions induced by H2O2 or glutamate. ROS levels are measured using fluorescent probes. AChE and MAO activity in cell lysates is measured using commercial assay kits.
|
| Animal Protocol |
Animal studies use rodent models. Parishin C is administered orally or intraperitoneally. The pentobarbital-induced sleep test is used to assess sedative-hypnotic effects. The elevated plus maze and open field tests are used to evaluate anxiety. Cognitive function is assessed using the Morris water maze or passive avoidance tests.
|
| ADME/Pharmacokinetics |
Parishin C is a glycoside with moderate hydrophilicity. As a natural product, it is expected to be absorbed and metabolized to gastrodin and other phenolic compounds. Detailed pharmacokinetic parameters are not well characterized in the literature. It likely undergoes phase II metabolism (glucuronidation and sulfation).
|
| Toxicity/Toxicokinetics |
Parishin C is considered to have low toxicity based on its long history of use in traditional medicine as a component of Gastrodia elata. No significant acute toxicity has been reported in animal studies. Comprehensive toxicological data are limited.
|
| References |
|
| Additional Infomation |
Reports indicate that wormwood and gastrodia elata contain Parishin C, and relevant data is available for reference.
Parishin C is a research compound with potential neuroprotective and sedative properties. It is not an approved drug and is not in clinical trials. It serves as a reference compound for studying the pharmacological activities of Gastrodia elata constituents and phenolic glycosides. |
| Molecular Formula |
C32H40O19
|
|---|---|
| Molecular Weight |
728.6486
|
| Exact Mass |
728.216
|
| CAS # |
174972-80-6
|
| PubChem CID |
10676408
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
1052.0±65.0 °C at 760 mmHg
|
| Flash Point |
331.2±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.650
|
| LogP |
-2.24
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
51
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=CC=C1COC(=O)CC(CC(=O)OCC2=CC=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)(C(=O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
PMVCHAWVCIWVLP-KDSCYBBXSA-N
|
| InChi Code |
InChI=1S/C32H40O19/c33-11-19-23(37)25(39)27(41)29(50-19)48-17-5-1-15(2-6-17)13-46-21(35)9-32(45,31(43)44)10-22(36)47-14-16-3-7-18(8-4-16)49-30-28(42)26(40)24(38)20(12-34)51-30/h1-8,19-20,23-30,33-34,37-42,45H,9-14H2,(H,43,44)/t19-,20-,23-,24-,25+,26+,27-,28-,29-,30-/m1/s1
|
| Chemical Name |
2-hydroxy-4-oxo-2-[2-oxo-2-[[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methoxy]ethyl]-4-[[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methoxy]butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~137.24 mM)
H2O : ≥ 100 mg/mL (~137.24 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3724 mL | 6.8620 mL | 13.7240 mL | |
| 5 mM | 0.2745 mL | 1.3724 mL | 2.7448 mL | |
| 10 mM | 0.1372 mL | 0.6862 mL | 1.3724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
